Gabapentin Capsule
Product Images NDC 70518-4493

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4493). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A mathematical formula for calculating creatinine clearance (CLCr), showing the relationship between age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor for female patients (multiplication by 0.85). This is a common clinical calculation used in drug dosing considerations.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Weekly Mean Pain Scores' showing observed cases in an ITT population for Study 1. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain scores from 1 to 10. Two lines compare placebo and gabapentin at 3600 mg/day, with gabapentin showing a declining trend in pain scores over time compared to a relatively stable placebo line.*

FDA Label Image

Fig 2 (Fig 2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day through the baseline, 3-week dose titration period, and 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10, and the x-axis shows weeks from baseline to 7.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies'. It compares response rates between placebo (PBO) and gabapentin (GBP) at different dosages in two studies, with percentages labeled for each group showing higher response for gabapentin groups. Statistical significance markers are included above some bars.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot figure showing responder rate difference (%) on the y-axis versus daily dose (mg) on the x-axis for gabapentin in patients aged 12 or older with partial seizures. The graph compares three studies (a, b, c) at doses of approximately 600, 900, 1200, and 1800 mg, indicating efficacy differences from placebo by dose and study.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Capsule 100 mg oral capsules packaging label with a quantity of 100 capsules. The label shows the RemedyRepack Inc. logo and states the capsules are white. It includes manufacturer information for Camber Pharma, Inc., in Piscataway, NJ, and storage instructions between 20-25°C with permissible excursions. The label notes repackaging by RemedyRepack Inc., Indiana, PA.*

FDA Label Image

Structure (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.